Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.86 |
| ▸ | ESR1 | P03372 | 4/20 | 0.60 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | DRD1 | P21728 | 2/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2651099 | 1.00 | TDP1 (0.86) | TDP1CYP3A4ESR1ESR2KDM4E | |
| Hydrochloric Acid SCHEMBL10878421 | 1.00 | TDP1 (0.86) | TDP1CYP3A4ESR1ESR2KDM4E | |
| Hydrochloric Acid SCHEMBL3932 | 1.00 | TDP1 (0.86) | TDP1CYP3A4ESR1ESR2KDM4E | |
| Hydrochloric Acid SCHEMBL7591449 | 1.00 | TDP1 (0.86) | TDP1CYP3A4ESR1ESR2KDM4E | |
| Hydrochloric Acid SCHEMBL7006332 | 1.00 | TDP1 (0.86) | TDP1CYP3A4ESR1ESR2KDM4E | |
| Hydrochloric Acid SCHEMBL31438532 | 1.00 | TDP1 (0.86) | TDP1CYP3A4ESR1ESR2KDM4E | |
| Hydrochloric Acid SCHEMBL8875 | 1.00 | TDP1 (0.86) | TDP1CYP3A4ESR1ESR2KDM4E | |
| Hydrochloric Acid SCHEMBL6232190 | 1.00 | TDP1 (0.86) | TDP1CYP3A4ESR1ESR2KDM4E | |
| Hydrochloric Acid SCHEMBL14714623 | 1.00 | TDP1 (0.86) | TDP1CYP3A4ESR1ESR2KDM4E | |
| Hydrochloric Acid SCHEMBL1525005 | 0.97 | TDP1 (0.80) | TDP1CYP3A4ESR1ESR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115894359-A | C-N axis chiral 4-quinolinone compound and preparation and application thereof | 中山大学 | 2023-04-04 | — | — | CN | claimed |
| CN-114805174-A | TMC-205, one-pot synthesis method and application | 大理大学 | 2022-07-29 | — | — | CN | claimed |
| CN-111154498-B | Preparation method of liquid crystal compound containing 1, 5-indan and difluoromethoxy bridge | 西安瑞联新材料股份有限公司 | 2021-10-22 | — | — | CN | claimed |
| CN-106928076-B | Lambda-type bromine-containing benzo [ b ] fluorenone compound with lyotropic discoloration and luminescence properties | 江西师范大学 | 2020-11-06 | — | — | CN | claimed |
| CN-111154498-A | Preparation method of liquid crystal compound containing 1, 5-indan and difluoromethoxy bridge | 西安瑞联新材料股份有限公司 | 2020-05-15 | — | — | CN | claimed |
| US-9604941-B2 | Preparation method of conjugated compound containing bis(phenylsulfonyl)benzene structure and an organic electroluminescent diode device using the conjugated compound | SHENZHEN CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD. (CN) | 2017-03-28 | — | — | US | claimed |
| US-20160322567-A1 | CONJUGATED COMPOUND CONTAINING BIS(PHENYLSULFONYL)BENZENE STRUCTURE, PREPARATION METHOD AND APPLICATION THEREOF | SHENZHEN CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD. (CN) | 2016-11-03 | — | — | US | claimed |
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4334303-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4334302-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20230404925-A1 | JAK INHIBITORS HAVING A SPECIFIC PARTICLE SIZE DISTRIBUTION | ELANCO US INC. | 2023-12-21 | — | — | US | disclosed |
| CN-117024388-A | Synthesis process of coumarin compound citreuntin | 大理大学 | 2023-11-10 | — | — | CN | disclosed |
| EP-4232000-A1 | JAK INHIBITORS HAVING A SPECIFIC PARTICLE SIZE DISTRIBUTION | Elanco US Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-5310746-A | Insecticides, miticides, nematocides | ROUSSEL UCLAF (FR) | 1994-05-10 | — | — | US | disclosed |
| EP-0591583-A1 | Benzo (f) quinolinones as 5-alpha-reductase inhibitors | ELI LILLY AND COMPANY (US) | 1994-04-13 | — | — | EP | disclosed |
| US-5239075-A | PROCESS FOR THE PREPARATION OF BENZO (F) QUINOLINONES | ELI LILLY AND COMPANY (US) | 1993-08-24 | — | — | US | disclosed |
| EP-0532190-A2 | Benzo f quinolinones as 5-alpha-reductase inhibitors | ELI LILLY AND COMPANY (US) | 1993-03-17 | — | — | EP | disclosed |
| WO-1992019618-A1 | PLATELET ACTIVATING ANTAGONISTS | ABBOTT LABORATORIES (US) | 1992-11-12 | — | — | WO | disclosed |
| US-5158957-A | Dopamine antagonist | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-10-27 | — | — | US | disclosed |
| US-5037832-A | Dopaminergic agents for treating Parkinson*s disease | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | ITK, NFATC1, TNIK | ACHE 3111/4885TDP1 1986/4885CYP3A4 4045/4885 |
| US-20230404925-A1 | JAK INHIBITORS HAVING A SPECIFIC PARTICLE SIZE DISTRIBUTION | JAK1, JAK3, JAK2 | ACHE 4862/4885TDP1 2547/4885CYP3A4 1175/4885 |
| US-20160322567-A1 | CONJUGATED COMPOUND CONTAINING BIS(PHENYLSULFONYL)BENZENE STRUCTURE, PREPARATION METHOD AND APPLICATION THEREOF | AOC1, DDT, KCNJ1 | ACHE 2793/4885TDP1 3993/4885CYP3A4 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.